Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma

Journal of Cellular Biochemistry

Volumn 113, Issue 2, 2012, Pages 419-425

  Goel, Apollina ^a   Spitz, Douglas R ^a   Weiner, George J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

B cell lymphoma; Chemotherapy drugs; Multiple myeloma; Oxidative stress; Radiotherapy

Indexed keywords

2 METHOXYESTRADIOL; ARSENIC TRIOXIDE; BORTEZOMIB; CATALASE; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; DEXAMETHASONE; DOCOSAHEXAENOIC ACID; DOXORUBICIN; ETOPOSIDE; GADOLINIUM TEXAPHYRIN; GLUTATHIONE PEROXIDASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYL RADICAL; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; IMEXON; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXYNITRITE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RITUXIMAB; SUPEROXIDE DISMUTASE; THALIDOMIDE; TOSITUMOMAB I 131; TROLOX C; UNINDEXED DRUG; VINCRISTINE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FOLLICULAR LYMPHOMA; GAMMA IRRADIATION; HUMAN; LARGE CELL LYMPHOMA; LIPID PEROXIDATION; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; ARSENICALS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXIDES; PYRAZINES; RADIOTHERAPY;

EID: 84855544030     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23387     Document Type: Review

References (77)

1. Al-Gayyar MM, Eissa LA, Rabie AM, El-Gayar AM. 2007. Measurements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol 59:409-417. (Pubitemid 47050906)
2. Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. 2001. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol 23:500-505. (Pubitemid 33123700)
3. Anderson KC, Carrasco RD. 2011. Pathogenesis of myeloma. Annu Rev Pathol 6:249-274.
4. Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ, Rebbeck TR. 2007. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 109:3409-3416. (Pubitemid 46572530)
5. Aramaki Y, Yotsumoto S, Watanabe H, Tsuchiya S. 2002. NADPH-oxidase may contribute to IL-12 production in macrophages stimulated with CpG phosphorothioate oligodeoxynucleotides. Biol Pharm Bull 25:351-355.
6. Armand JP, Burnett AK, Drach J, Harousseau JL, Lowenberg B, San Miguel J. 2007. The emerging role of targeted therapy for hematologic malignancies: Update on bortezomib and tipifarnib. Oncologist 12:281-290. (Pubitemid 46556794)
7. Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR. 2009. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 418:29-37.
8. Battisti V, Maders LD, Bagatini MD, Santos KF, Spanevello RM, Maldonado PA, Brule AO, Araujo Mdo C, Schetinger MR, Morsch VM. 2008. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem 41:511-518.
9. Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Esteve J, Campo E, Colomer D, Montserrat E. 2001. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98:2771-2777.
10. Bera S, Greiner S, Choudhury A, Dispenzieri A, Spitz DR, Russell SJ, Goel A. 2010. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. Neoplasia 12:980-992.
11. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA. 2009. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 15:1069-1075.
12. Berges O, Decaudin D, Servois V, Kirova YM. 2008. Concurrent radiation therapy and bortezomib in myeloma patient. Radiother Oncol 86:290-292.
13. Brasseur N, Menard I, Forget A, el Jastimi R, Hamel R, Molfino NA, van Lier JE. 2000. Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: Implication for clinical ex vivo purging of autologous stem cell transplants. Photochem Photobiol 72:780-787.
14. Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD, Jr. 2008. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 14:4821-4829.
15. Chang J, Voorhees P, Kolesar J, Ahuja H, Sanchez F, Rodriguez G, Kim K, Werndli J, Bailey H, Kahl B. 2008. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A Wisconsin Oncology Network study. Hematol Oncol 27:11-16.
16. Chauhan D, Li G, Auclair D, Hideshima T, Podar K, Mitsiades N, Mitsiades C, Chen LB, Munshi N, Saxena S, Anderson KC. 2004. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis 9:149-155. (Pubitemid 38987592)
17. Dalton WS. 2002. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002. Clin Cancer Res 8:3643-3645.
18. Diaz Z, Laurenzana A, Mann KK, Bismar TA, Schipper HM, Miller WH Jr. 2007. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia 21:2117-2127. (Pubitemid 47430453)
19. Dougall WC, Nick HS. 1991. Manganese superoxide dismutase: A hepatic acute phase protein regulated by interleukin-6 and glucocorticoids. Endocrinology 129:2376-2384.
20. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. 2007. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced antimultiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 139:385-397. (Pubitemid 47512171)
21. Finkel T, Holbrook NJ. 2000. Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247.
22. Fribley A, Zeng Q, Wang CY. 2004. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:9695-9704. (Pubitemid 39458799)
23. Gilmore TD. 2007. Multiple myeloma: Lusting for NF-kappaB. Cancer Cell 12:95-97.
24. Gius D, Spitz DR. 2006. Redox signaling in cancer biology. Antioxid Redox Signal 8:1249-1252. (Pubitemid 44182423)
25. Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT, Bell JC, Russell SJ. 2007. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110:2342-2350. (Pubitemid 47523154)
26. Goel A, Dispenzieri A, Geyer SM, Greiner S, Peng KW, Russell SJ. 2006a. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 107:4063-4070. (Pubitemid 43726815)
27. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ. 2005. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 33:784-795. (Pubitemid 40826592)
28. Goel A, Dispenzieri A, Witzig TE, Russell SJ. 2006b. Enhancing the therapeutic index of radiation in multiple myeloma. Drug Discov Today Dis Mech 3:515-522.
29. Golab J, Nowis D, Skrzycki M, Czeczot H, Baranczyk-Kuzma A, Wilczynski GM, Makowski M, Mroz P, Kozar K, Kaminski R, Jalili A, Kopec M, Grzela T, Jakobisiak M. 2003. Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem 278:407-414. (Pubitemid 36043590)
30. Han SS, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S. 2005. Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 94:695-707. (Pubitemid 41420269)
31. Han W, Takano T, He J, Ding J, Gao S, Noda C, Yanagi S, Yamamura H. 2001. Role of BLNK in oxidative stress signaling in B cells. Antioxid Redox Signal 3:1065-1073. (Pubitemid 34027362)
32. Hannah AL. 2005. Kinases as drug discovery targets in hematologic malignancies. Curr Mol Med 5:625-642. (Pubitemid 41824226)
33. Harousseau JL, Shaughnessy J Jr, Richardson P. 2004. Multiple myeloma. Hematology Am Soc Hematol Educ Program 237-256.
34. Hodge DR, Peng B, Pompeia C, Thomas S, Cho E, Clausen PA, Marquez VE, Farrar WL. 2005. Epigenetic silencing of manganese superoxide dismutase (SOD-2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. Cancer Biol Ther 4:585-592. (Pubitemid 41351234)
35. Hofmeister CC, Jansak B, Denlinger N, Kraut EH, Benson DM, Farag SS. 2008. Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leuk Res 32:1295-1298.
36. Hurt EM, Thomas SB, Peng B, Farrar WL. 2007. Integrated molecular profiling of SOD2 expression in multiple myeloma. Blood 109:3953-3962. (Pubitemid 46641748)
37. Hussein MA. 2003. Trials of arsenic trioxide in multiple myeloma. Cancer Control 10:370-374. (Pubitemid 37296063)
38. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69-90.
39. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. 2008. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 141:135-148. (Pubitemid 351406208)
40. Kirsch JD, Yi AK, Spitz DR, Krieg AM. 2002. Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA. Antisense Nucleic Acid Drug Dev 12:327-340. (Pubitemid 35375497)
41. Klaunig JE, Kamendulis LM. 2004. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239-267. (Pubitemid 38263841)
42. Kuku I, Aydogdu I, Bayraktar N, Kaya E, Akyol O, Erkurt MA. 2005. Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem Funct 23:47-50. (Pubitemid 40065172)
43. Kundu JK, Surh YJ. 2008. Inflammation: Gearing the journey to cancer. Mutat Res 659:15-30.
44. Lazar AD, Shpilberg O, Shaklai M, Bairey O. 2009. Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma. Isr Med Assoc J 11:16-22.
45. LeBien TW, Tedder TF. 2008. B lymphocytes: How they develop and function. Blood 112:1570-1580.
46. Lee JG, Lee SH, Park DW, Yoon HS, Chin BR, Kim JH, Kim JR, Baek SH. 2008. Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A2-ROS signaling. Cell Signal 20:105-111.
47. Leonard JP, Furman RR, Coleman M. 2006. Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer 119:971-979. (Pubitemid 44121415)
48. Lightfoot TJ, Skibola CF, Smith AG, Forrest MS, Adamson PJ, Morgan GJ, Bracci PM, Roman E, Smith MT, Holly EA. 2006. Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica 91:1222-1227. (Pubitemid 44408432)
49. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, Rasmussen WL, Krieg AM, Weiner GJ. 2006. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29:558-568. (Pubitemid 44395280)
50. Marchand V, Decaudin D, Servois V, Kirova YM. 2008. Concurrent radiation therapy and lenalidomide in myeloma patient. Radiother Oncol 87:152-153.
51. Mazor D, Abucoider A, Meyerstein N, Kapelushnik J. 2008. Antioxidant status in pediatric acute lymphocytic leukemia (ALL) and solid tumors: The impact of oxidative stress. Pediatr Blood Cancer 51:613-615.
52. Mendes RV, Martins AR, de Nucci G, Murad F, Soares FA. 2001. Expression of nitric oxide synthase isoforms and nitrotyrosine immunoreactivity by B-cell non-Hodgkin's lymphomas and multiple myeloma. Histopathology 39:172-178. (Pubitemid 34225044)
53. Mone AP, Huang P, Pelicano H, Cheney CM, Green JM, Tso JY, Johnson AJ, Jefferson S, Lin TS, Byrd JC. 2004. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 103:1846-1854. (Pubitemid 38268982)
54. Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B. 2002. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16:1835-1837.
55. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R. 2008. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol 141:494-503. (Pubitemid 351550556)
56. Oberley LW, Buettner GR. 1979. Role of superoxide dismutase in cancer: A review. Cancer Res 39:1141-1149. (Pubitemid 9183825)
57. Ono M, Kohda H, Kawaguchi T, Ohhira M, Sekiya C, Namiki M, Takeyasu A, Taniguchi N. 1992. Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells. Biochem Biophys Res Commun 182:1100-1107.
58. Pei XY, Dai Y, Grant S. 2003. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17:2036-2045. (Pubitemid 37322135)
59. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. 2002. Current therapy for multiple myeloma. Mayo Clin Proc 77:813-822. (Pubitemid 34851268)
60. Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC, Gertz MA. 2007. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 13:6162-6167. (Pubitemid 350075076)
61. Renschler MF. 2004. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 40:1934-1940. (Pubitemid 39094687)
62. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC. 2005. Bortezomib or high-dose for relapsed multiple myeloma. N Engl J Med 352:2487-2498. (Pubitemid 41007864)
63. Schaefer-Cutillo J, Friedberg JW, Fisher RI. 2007. Novel concepts in radio-immunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park) 21:203-212; discussion 214, 217, 221.
64. Schafer FQ, Buettner GR. 2001. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191-1212. (Pubitemid 32463931)
65. Spitz DR, Azzam EI, Li JJ, Gius D. 2004. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: A unifying concept in stress response biology. Cancer Metastasis Rev 23:311-322. (Pubitemid 38881814)
66. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. 2000. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann NY Acad Sci 899:349-362. (Pubitemid 30352799)
67. Szatrowski TP, Nathan CF. 1991. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51:794-798.
68. Tohyama Y, Takano T, Yamamura H. 2004. B cell responses to oxidative stress. Curr Pharm Des 10:835-839. (Pubitemid 38380062)
69. Tome ME, Johnson DB, Rimsza LM, Roberts RA, Grogan TM, Miller TP, Oberley LW, Briehl MM. 2005. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood 106:3594-3601. (Pubitemid 41609198)
70. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. 2008. Redox regulation of cell survival. Antioxid Redox Signal 10:1343-1374.
71. Van de Velde AL, Berneman ZN, Van Tendeloo VF. 2008. Immunotherapy of hematological malignancies using dendritic cells. Bull Cancer 95:320-326. (Pubitemid 351528769)
72. Villamor N, Montserrat E, Colomer D. 2004. Cytotoxic effects of B lymphocytes mediated by reactive oxygen species. Curr Pharm Des 10:841-853. (Pubitemid 38380063)
73. Wang SS, Davis S, Cerhan JR, Hartge P, Severson RK, Cozen W, Lan Q, Welch R, Chanock SJ, Rothman N. 2006. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis 27:1828-1834. (Pubitemid 44288664)
74. Witzig TE. 2006. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol 19:655-668. (Pubitemid 44391348)
75. Zhou L, Hou J, Fu W, Wang D, Yuan Z, Jiang H. 2008. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res 32:1674-1683.
76. Zhu Q, Chen G, Huang Y. 2000. [The relationship between sensitivity to arsenic trioxide and antioxidative capacity of malignant hematopoietic cells]. Zhonghua Zhong Liu Za Zhi 22:359-361.
77. Zima T, Spicka I, Stipek S, Crkovska J, Platenik J, Merta M, Tesar V. 1996. Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma. Neoplasma 43:69-73. (Pubitemid 26166214)